MEDCL Fundamental Analysis - MEDINCELL SA

Name: MEDINCELL SA (MEDCL) Stock
Brand: MEDINCELL SA
Rating: 6 (3 reviews)

Fundamental Rating

Overall MEDCL gets a fundamental rating of 4 out of 10. We evaluated MEDCL against 54 industry peers in the Pharmaceuticals industry. MEDCL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MEDCL shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

MEDCL had negative earnings in the past year.

In the past year MEDCL had a positive cash flow from operations.

In the past 5 years MEDCL always reported negative net income.

In the past 5 years MEDCL reported 4 times negative operating cash flow.

1.2 Ratios

MEDCL's Return On Assets of -20.38% is on the low side compared to the rest of the industry. MEDCL is outperformed by 77.78% of its industry peers.

		Industry Rank	Sector Rank
ROA	-20.38%
ROE	N/A
ROIC	N/A

ROA(3y)-65.75%

ROA(5y)-56.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of MEDCL (95.46%) is better than 96.30% of its industry peers.

In the last couple of years the Gross Margin of MEDCL has grown nicely.

MEDCL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.46%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.72%

GM growth 5Y7.65%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.

MEDCL has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, MEDCL has more shares outstanding

MEDCL has a better debt/assets ratio than last year.

2.2 Solvency

MEDCL has an Altman-Z score of 4.69. This indicates that MEDCL is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of MEDCL (4.69) is better than 72.22% of its industry peers.

MEDCL has a debt to FCF ratio of 3.30. This is a good value and a sign of high solvency as MEDCL would need 3.30 years to pay back of all of its debts.

With a Debt to FCF ratio value of 3.30, MEDCL perfoms like the industry average, outperforming 59.26% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	3.3
Altman-Z	4.69

ROIC/WACCN/A

WACC7.81%

2.3 Liquidity

A Current Ratio of 2.70 indicates that MEDCL has no problem at all paying its short term obligations.

MEDCL has a better Current ratio (2.70) than 87.04% of its industry peers.

MEDCL has a Quick Ratio of 2.70. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of MEDCL (2.70) is better than 88.89% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.7
Quick Ratio	2.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.16% over the past year.

Looking at the last year, MEDCL shows a very strong growth in Revenue. The Revenue has grown by 181.43%.

The Revenue has been growing by 54.88% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)28.16%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.59%

Revenue 1Y (TTM)181.43%

Revenue growth 3Y83.86%

Revenue growth 5Y54.88%

Sales Q2Q%720.66%

3.2 Future

MEDCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.22% yearly.

MEDCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.22% yearly.

EPS Next Y78.94%

EPS Next 2Y100.37%

EPS Next 3Y74.94%

EPS Next 5Y50.22%

Revenue Next Year22.24%

Revenue Next 2Y62.91%

Revenue Next 3Y76.73%

Revenue Next 5Y40.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MEDCL. In the last year negative earnings were reported.

Also next year MEDCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, MEDCL is valued a bit more expensive than the industry average as 62.96% of the companies are valued more cheaply.

		Industry Rank	Sector Rank
P/FCF	55.54
EV/EBITDA	N/A

4.3 Compensation for Growth

MEDCL's earnings are expected to grow with 74.94% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y100.37%

EPS Next 3Y74.94%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MEDCL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDINCELL SA

EPA:MEDCL (11/11/2025, 12:04:50 PM)

29.88

+0.4 (+1.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)06-17 2025-06-17/amc

Earnings (Next)12-09 2025-12-09

Inst Owners31.05%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap989.03M

Revenue(TTM)25.42M

Net Income(TTM)-18.44M

Analysts85.88

Price Target33.91 (13.49%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)32.18%

PT rev (3m)43.75%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-15.74%

EPS NY rev (3m)-153.51%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)8.46%

Revenue NY rev (3m)-9.56%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	38.91
P/FCF	55.54
P/OCF	50.81
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.63

EYN/A

EPS(NY)-0.16

Fwd EYN/A

FCF(TTM)0.54

FCFY1.8%

OCF(TTM)0.59

OCFY1.97%

SpS0.77

BVpS-0.49

TBVpS-0.57

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.38%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.46%
FCFM	70.05%

ROA(3y)-65.75%

ROA(5y)-56.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.72%

GM growth 5Y7.65%

F-Score7

Asset Turnover0.28

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	3.3
Debt/EBITDA	N/A
Cap/Depr	83.42%
Cap/Sales	6.53%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.7
Quick Ratio	2.7
Altman-Z	4.69

F-Score7

WACC7.81%

ROIC/WACCN/A

Cap/Depr(3y)71.46%

Cap/Depr(5y)81.14%

Cap/Sales(3y)10.03%

Cap/Sales(5y)17.67%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)28.16%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.59%

EPS Next Y78.94%

EPS Next 2Y100.37%

EPS Next 3Y74.94%

EPS Next 5Y50.22%

Revenue 1Y (TTM)181.43%

Revenue growth 3Y83.86%

Revenue growth 5Y54.88%

Sales Q2Q%720.66%

Revenue Next Year22.24%

Revenue Next 2Y62.91%

Revenue Next 3Y76.73%

Revenue Next 5Y40.22%

EBIT growth 1Y48.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year132.01%

EBIT Next 3Y116.45%

EBIT Next 5YN/A

FCF growth 1Y235.79%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y263.28%

OCF growth 3YN/A

OCF growth 5YN/A

MEDINCELL SA / MEDCL.PA FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.

What is the valuation status of MEDINCELL SA (MEDCL.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.

What is the profitability of MEDCL stock?

MEDINCELL SA (MEDCL.PA) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for MEDCL stock?

The Earnings per Share (EPS) of MEDINCELL SA (MEDCL.PA) is expected to grow by 78.94% in the next year.

MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDINCELL SA / MEDCL.PA FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

What is the valuation status of MEDINCELL SA (MEDCL.PA) stock?

What is the profitability of MEDCL stock?

Can you provide the expected EPS growth for MEDCL stock?